MSTX : Summary for Mast Therapeutics, Inc. Common - Yahoo Finance

U.S. Markets open in 8 hrs 28 mins

Mast Therapeutics, Inc. (MSTX)


NYSE MKT - NYSE MKT Real Time Price. Currency in USD
Add to watchlist
0.08-0.01 (-6.36%)
At close: 4:00 PM EST
People also watch:
RNNIMUCIMNPPTXSPHS
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close0.09
Open0.08
Bid0.08 x 12400
Ask0.09 x 84800
Day's Range0.07 - 0.08
52 Week Range0.07 - 0.71
Volume4,299,555
Avg. Volume10,806,066
Market Cap19.3M
Beta-0.97
PE Ratio (TTM)-0.38
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • PR Newswire14 days ago

    Mast Therapeutics Provides Update On Strategic Direction

    Other Strategic Opportunities.  Concurrently, the Company will continue to explore ways to strategically monetize its vepoloxamer assets, including through licensing transactions. "Our recently-announced strategic process has generated a number of opportunities that would be transformative for Mast," stated Brian M. Culley, Chief Executive Officer of Mast Therapeutics.  "We are diligently and expeditiously reviewing these strategic alternatives, which we believe could maximize returns for our stockholders. The Company has two clinical-stage investigational new drugs, AIR001 and vepoloxamer.  AIR001, a sodium nitrite solution for intermittent inhalation via nebulization, is in Phase 2 clinical development for the treatment of heart failure with preserved ejection fraction (HFpEF).

  • Investopedia25 days ago

    Mast Therapeutics 3Q Loss 8.2M or 4c/Share (MSTX)

    Mast Therapeutics reported a third-quarter loss of 8.2 million, compared to $9.9 million last year.

  • Associated Press27 days ago

    Mast reports 3Q loss

    The San Diego-based company said it had a loss of 4 cents per share. The biopharmaceutical company posted revenue of $45,000 in the period. The company's shares closed at 7 cents. A year ago, they were ...